Impaired mineral homeostasis affecting calcium, phosphate, and magnesium is a result of parathyroid hormone (PTH) deficiency in hypoparathyroidism. Parathyroid hormone, (PTH) is an adjunct drug to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The current article highlights the potential role of this recently approved FDA drug. Hypoparathyroidism is an endocrine disorder characterized by insufficient levels of PTH.
People with hypoparathyroidism have limited treatment options and face challenging symptoms that can severely impact their quality of life. The standard of care available at the moment is oral supplementation with calcium and active vitamin D, but this provides inadequate and inconsistent regulation of biochemical indices. It can also cause severe long-term complications and often requires patients to take large amounts of oral calcium and…
